, Tracking Stock Market Picks
Enter Symbol:
Bio-rad Laboratories, Inc. (BIO) [hlAlert]

up 47.16 %

Bio-rad Laboratories, Inc. (BIO) rated Buy with price target $125 by Maxim Group

Posted on: Friday,  Dec 18, 2009  8:25 AM ET by Maxim Group

Maxim Group rated Buy Bio-rad Laboratories, Inc. (NYSE: BIO) on 12/18/2009, when the stock price was $95.99. Since
then, Bio-rad Laboratories, Inc. has gained 47.16% as of 01/13/2016's recent price of $141.26.
If you would have followed this Maxim Group's recommendation on BIO, you would have gained 47.16% of your investment in 2217 days.

Bio-Rad Laboratories, Inc. (Bio-Rad) manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. During the year ended December 31, 2008, the Company acquired additional shares of DiaMed Holding AG, bringing its total ownership to 93.46%.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/18/2009 8:25 AM Buy
95.99 125.00
as of 12/31/2009
1 Week up  12.34 %
1 Month up  14.58 %
3 Months   
1 YTD up  14.58 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy